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A Ab bs st tr ra ac ct t
The Swedish Family-Cancer Database has been used for almost 10 years in the study of familial risks at all common
sites. In the present paper we describe some main features of version VI of this Database, assembled in 2004. 
This update included all Swedes born in 1932 and later (offspring) with their biological parents, a total of 10.5
million individuals. Cancer cases were retrieved from the Swedish Cancer Registry from 1958-2002, including
over 1.2 million first and multiple primary cancers and in situ tumours. Compared to previous versions, only 6.0%
of deceased offspring with a cancer diagnosis lack any parental information. We show one application of the
Database in the study of familial risks in colorectal adenocarcinoma, with defined age-group and anatomic site
specific analyses. Familial standardized incidence ratios (SIRs) were determined for offspring when parents or sibling
were diagnosed with colon or rectal cancer. As a novel finding it was shown that risks for siblings were higher than
those for offspring of affected parents. The excess risk was limited to colon cancer and particularly to right-sided
colon cancer. The SIRs for colon cancer in age matched populations were 2.58 when parents were probands and
3.81 when siblings were probands; for right-sided colon cancer the SIRs were 3.66 and 7.53, respectively. 
Thus the familial excess (SIR-1.00) was more than two fold higher for right-sided colon cancer. Colon and rectal
cancers appeared to be distinguished between high-penetrant and recessive conditions that only affect the colon,
whereas low-penetrant familial effects are shared by the two sites. Epidemiological studies can be used to generate
clinical estimates for familial risk, conditioned on numbers of affected family members and their ages of onset.
Useful risk estimates have been developed for familial breast and prostate cancers. Reliable risk estimates for other
cancers should also be seriously considered for routine clinical recommendations, because practically all cancers
show a familial effect and the risks are high for some of the rare neoplasms. The implementation of a unified
management plan for familial cancers at large will be a major challenge to the clinical genetic counselling community. 
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I In nt tr ro od du uc ct ti io on n   
The majority of cancers are sporadic and some 
1-5% are due to single-gene, dominant traits [1]. There
are no estimates on the contribution of polygenic or
recessive conditions on cancer, but twin studies suggest
that such effects are important [2]. Familial aggregation
of cancer may be due to environmental factors shared
by  family  members  or  due  to  shared  genes.H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(1) 8
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T Ta ab bl le e   1 1. .   N Nu um mb be er r   o of f   c ca an nc ce er r   n no ot ti if fi ic ca at ti io on ns s   f fo or r   f fi ir rs st t   a an nd d   m mu ul lt ti ip pl le e   p pr ri im ma ar ry y   i in nv va as si iv ve e   a an nd d   i in n   s si it tu u   c ca an nc ce er rs s   i in n   t th he e   F Fa am mi il ly y- -C Ca an nc ce er r   D Da at ta ab ba as se e, ,   1 19 95 58 8- -2 20 00 02 2
F Fi ir rs st t   p pr ri im ma ar ry y M Mu ul lt ti ip pl le e   p pr ri im ma ar ry y I In n   s si it tu u A Al ll l
Father 315,921 37,379 30,057 383,357
Mother 270,039 33,676 64,203 367,918
Father/son 65,269 3,832 6,982 76,083
Mother/daughter 97,442 7,658 114,976 220,076
Son 24,230 1,105 1,752 27,087
Daughter 23,075 1,614 18,671 43,360
All 795,976 85,264 236,641 1,117,881
Observation  of  familial  aggregation  has  been
important for the understanding of cancer aetiology,
for  clinical  decisions  and  counselling  and  for
identification of cancer-related genes. Our comparisons
of familial cancer risks between spouses, and between
parents  and  offspring  suggest  that  the  known
environmental factors explain familial aggregation for
lung and gastric cancer and for melanoma, but only
to a limited degree. At the remaining sites inherited
factors appear to be the main cause [3]. 
Familial clustering of cancer has been studied
through clinical identification of probands and multiple
affected family members [1, 4]. This approach has
been very productive also in terms of understanding
cancer genetics. Many forms of cancer in which
a single gene poses a high risk have been identified.
The disadvantages include difficulties in obtaining large
numbers of cases and in securing unbiased risk
estimates. Also estimation of risks at sites other than
the  index  site  has  been  cumbersome.  Clinical
observation probably works for dominant diseases
where risks are between 10 and 100, or more. For
recessive conditions, it is less sensitive, and most results
on recessive conditions have come from an isolated
population  with  high  rates  of  consanguineous
marriage. Population geneticists have raised questions
about a relatively small number of known human
recessive syndromes. In species of experimental animals
recessive traits predominate as opposed to humans
where dominant traits are more common [5]. It is not
excluded that this is an observation bias because of
difficulties in identifying a recessive pattern. 
A major problem in the global literature on familial
cancer, which overwhelmingly consists of case-control
studies, is the possible inaccuracy of data on cancer
in family members who had died a long time before
the study. In hardly any study, except those based on
registers, are cancer diagnoses confirmed both for the
cases and the probands. The false reporting for internal
cancers  may  be  as  high  as  50%.  This  level  of
inaccuracy may cause a severe bias in the derived risk
estimates, with a tendency to report exaggerated risks,
in the most commonly used case-control studies [6].
A second problem is that all studies have been small
and it has been difficult to obtain reliable information
on familial aggregation of rare cancers. Overall, formal
epidemiological studies have had little impact on
defining new familial traits. They have been hypothesis
either generating or quantifying the known risks. 
The  Utah  Population  Database  has  been  used  in
quantifying known risks [7] or in gene identification. 
The largest dataset on familial cancer is the Swedish
Family-Cancer Database. In the present article we report
on 2004 update of this resource, and show an application
of the Database on colorectal cancer. Additionally we
discuss the application of epidemiologically derived risk
estimates in clinical genetic counselling. 
T Th he e   F Fa am mi il ly y- -C Ca an nc ce er r   D Da at ta ab ba as se e   a as s   o of f   2 20 00 04 4
Statistics  Sweden  created  a family  database,
”Second Generation Register” in 1995 [8]. After a few
expansions, it covered offspring born after 1931 with
their parents, and it was renamed to ”Multigeneration
Register”. We have linked the Second Generation
Register to the Swedish Cancer Registry (started in
1958) to make the Family-Cancer Database in five
expanded versions in 1996, 1997, 1999, 2000 and
2002. The number of cancers in the second generation
increased from 20,000 in 1996 to 158,000 in 2000;
in the parental generation the increase was from
500,000 to 602,663 invasive cancers. In the most
recent update, version VI, completed in 2004, the
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offspring generation has increased to 224,000. In the
Family-Cancer Database all data are organized in
child-mother-father triplets; the parents have been
registered at the time of birth of the child, allowing
tracking of ”biological” parents in spite of divorce and
remarriage. The national personal identification code
(personnummer) has been deleted from the Database. 
Version VI of the Database identified a total of 10.5
million persons, of whom 1,075,597 patients were
diagnosed with any tumour (Table 1). These included
795,976 first primary cancers, 85,264 multiple primaries
and 236,641 in situ cancers, distributed between the
generations. The annual accumulation of cancer cases
to  the  parental  and  offspring  generation  in  the
Family-Cancer Database is shown in Fig. 1. The offspring
generation has far fewer cases than the parental one but
the increase among the offspring generation is steep due
to the advancing age. The ‘All’ curve is the sum of the
three other mutually exclusive curves. 
The linkage of offspring to their parents was partially
incomplete among the deceased individuals, particularly
among those who were born in the 1930s and who died
before the 1990s. According to Table 2, 3.0% of the
7.4 million offspring had cancer, and 97.8% had a link
to at least one parent. The linkage was 98.6% among
those alive as of the end of 2002. Among the deceased
289,458 individuals, the linkage existed among 79.5%.
Parental information was lacking on 17,318 deceased
offspring, who had been diagnosed with cancer; this
was 6.0% of the deceased offspring and implied that
T Ta ab bl le e   2 2. .   N Nu um mb be er r   o of f   o of ff fs sp pr ri in ng g   i in n   t th he e   F Fa am mi il ly y- -C Ca an nc ce er r   D Da at ta ab ba as se e   i in n   1 19 95 58 8- -2 20 00 02 2
T To ot ta al l   n no o. .    O Of ff fs sp pr ri in ng g    O Of ff fs sp pr ri in ng g   l li in nk ke ed d       O Of ff fs sp pr ri in ng g   w wi it th h   c ca an nc ce er r   
o of f   o of ff fs sp pr ri in ng g w wi it th h   c ca an nc ce er r t to o   p pa ar re en nt t n no ot t   l li in nk ke ed d   t to o   p pa ar re en nt t
n n n n % % n n % % n n % %
All 7,400,436 224,225 3.0 7,240,222 97.8 26,254 0.4
Living offspring 7,100,978 144,602 2.0 7,010,092 98.6 8,936 0.1
Deceased offspring 289,458 79,623 27.5 230,130 79.5 17,318 6.0
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T Ta ab bl le e   3 3. .   S SI IR R   f fo or r   o of ff fs sp pr ri in ng g   C CR RC C   d de ep pe en nd di in ng g   o on n   t th he e   C CR RC C   i in n   p pr ro ob ba an nd ds s
F Fa am mi il li ia al l
P Pa ar re en nt t   o on nl ly y S Si ib bl li in ng g   o on nl ly y P Pa ar re en nt t   a an nd d   S Si ib bl li in ng g
c ca an nc ce er r   s si it te e
O O
1 1) ) E E S SI IR R 9 95 5% %C CI I O O
1 1) ) E E S SI IR R 9 95 5% %C CI I O O E E S SI IR R 9 95 5% %C CI I
Colon 448 239.40 1 1. .8 87 7 1.70 2.05 68 21.70 3 3. .1 13 3 2.43 3.97 13 1.50 8 8. .7 73 3 4.63 14.97
Rectum 227 141.30 1 1. .6 61 1 1.40 1.83 30 14.10 2 2. .1 13 3 1.44 3.04 1 0.40 2 2. .2 24 4 0.00 12.81
Colorectum 664 376.30 1 1. .7 76 6 1.63 1.90 93 34.30 2 2. .7 71 1 2.19 3.32 17 3.30 5 5. .0 08 8 2.95 8.16
Bold type, 95% CI does not include 1.00. 
1)Some observed numbers do not add up because in addition to the right- and left-sided colon cancer, multiple and unspecified colon tumours were included. 
0.4% of all offspring with cancer had no links to parents.
Offspring who died before 1960 are completely missing
from the Database. The records have been practically
complete since 1990 when the overwhelming majority
of familial cancers were recorded [9]. 
A relevant question is the generalisability of the
Swedish results to the mankind at large. We believe
that  the  results  are  generalisable  to  the  world
population which has approximately the same level of
cancer, i.e. developed countries. However, considering
that  for  some  familial  risks  ”gene-environment”
interactions may play a role, some caution needs to
be  exercised  when  making  extrapolations  to
populations whose cancer incidence is appreciably
different from that in the Nordic countries. Consistently,
the estimates of familial risk for breast and colorectal
cancer between various populations have not shown
evidence of population-dependent variation [10, 11].
Moreover, in a series of studies on cancer risks among
the Swedish immigrant populations, no differences in
cancer risk have been found between the second
generation immigrants and Swedes [12-14]. According
to a recent review, racial differences are small in
complex diseases, including cancer [15]. 
A Ap pp pl li ic ca at ti io on n   o of f   t th he e   D Da at ta ab ba as se e: :   
c co ol lo or re ec ct ta al l   c ca an nc ce er r
A family history of colorectal cancer (CRC) is a risk
factor for CRC, the contribution of which to all CRC
ranges, depending on the definition, from 7% for
co-aggregation in nuclear families to 35% for clustering
among  twins  [2,  16,  17].  The  most  common
Mendelian  condition,  hereditary  nonpolyposis
colorectal cancer (HNPCC) features a relatively early
onset (average 45 years) and preferential involvement
of the right-sided colon [17]. It affects also other sites,
such as the endometrium, pancreas, ovary, stomach
and upper urothelial tract. It has been estimated to
account for 3% of all CRC in Finland [18, 19] and
around 1% in Sweden and the USA [20-22], the
variation depending on many parameters, including
the age structure of the studied population and the
existence of founder mutations. Familial adenomatous
polyposis (FAP), Peutz-Jeghers syndrome, familial
juvenile polyposis and Cowden’s disease are other
syndromes in which CRC may be a manifestation [17,
23,  24].  All  these  Mendelian  conditions  follow
a dominant mode of inheritance. Recent data indicate
that recessive germline mutations in the MYH gene may
also increase the risk of CRC [25-28]. The suggested
role for the BML in CRC has not been confirmed [29,
30]. Even some other low-penetrant genes may also
contribute  to  familial  risk  [31-34].  The  pending
questions regarding familial CRC are characteristics of
the conditions which cannot be accounted for by the
known syndromes, including their mode of inheritance.
Furthermore, any unique familial risks at anatomic
subsites of CRC are of interest. For the interpretation
of  familial  risks,  it  is  important  to  estimate  the
contribution of environmental sharing to familial
clustering. We have recently concluded, by comparing
risks for CRC between various family members, that
the familial clustering of CRC is mainly due to heritable
causes [35]. 
We use the Family-Cancer Database, version V, to
examine some outstanding questions about familial
CRC. We analyse the risk of colorectal adenocarcinoma
in offspring whose parents or siblings present with these
cancers, by adhering specifically to adenocarcinoma
and  considering  colonic  subsites.  Standardized
incidence ratios (SIRs) were calculated for offspring
CRC as the ratio of observed (O) to expected (E)
number  of  cases.  The  expected  numbers  were
calculated from 5-year-age-, sex-, period- (10-year
bands),  area-  (county),  socio-economic  status
standardized rates [36]. Confidence intervals (95% CI)
were calculated assuming a Poisson distribution [36].
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dependence between the affected pairs was taken into
consideration [37]. The SIRs for offspring and siblings
when parent-only, sibling-only and parent and sibling
together being probands of different cancers were
calculated respectively. 
F Fa am mi il li ia al l  r ri is sk k  o of f  C CR RC C  i in n  o of ff fs sp pr ri in ng g
The Family-Cancer Database (version V) covered
years 1958 to 2000 from the Swedish Cancer Registry
and included 11,921 offspring and 80,196 parents with
CRCs of adenocarcinoma histology. Because we only
covered adenocarcinoma histology, the term CRC later
in this study refers to this histology only. Among affected
offspring (age 0-68 years), 664 had a parent, 93
a sibling and 17 both a parent and sibling diagnosed
with CRC (Table 3). The familial risk was somewhat
higher for colon than for rectal cancer but the difference
was higher (SIR 3.13 for colon and 2.13 for rectal
cancer) with a fraternal (sibling) proband compared to
a parental proband (SIR 1.87 for colon and 1.61 for
rectal cancer). When both a parent and a sibling were
affected, only colon cancer was increased (SIR 8.73). 
Age-specific SIRs of CRC in offspring by proband
CRC are shown in Table 4. The SIR for colon cancer
was 2.02 when parents were diagnosed with colon
cancer. SIR for colon cancer in siblings was 3.81 and
it was 13.39 when additionally a parent was affected.
The SIR for concordant rectal cancer in offspring and
parents was 1.77 and that among siblings was 1.96,
of borderline significance. The highest SIRs were found
for concordant right-sided colon cancer. The SIR for
offspring of affected parents was 2.45, for siblings it
was 6.89 and for families of affected parents and
offspring it was 34.62. The SIRs for siblings were also
vastly increased when the pairs presented with right-
and left-sided colon cancer (5.16 and 4.56); however,
no significant increase was found for siblings presenting
with right-sided colon and rectal cancers. 
The direct comparison of risks between offspring of
affected parents and siblings requires that ages of the
populations are similar, which is not the case in Table
3 and 4 because parents are of any age and all siblings
are below the age of 69 years. When the parental age
was limited to 68 years and younger, the SIR for colon
T Ta ab bl le e   4 4. .   S SI IR R   f fo or r   c co ol lo or re ec ct ta al l   a ad de en no oc ca ar rc ci in no om ma a   s su ub bs si it te es s   i in n   o of ff fs sp pr ri in ng g   b by y   p pr ro ob ba an nd d   c co ol lo or re ec ct ta al l   a ad de en no oc ca ar rc ci in no om ma a
P Pr ro ob ba an nd d   s su ub bs si it te e
O Of ff fs sp pr ri in ng g P Pr ro ob ba an nd d R Ri ig gh ht t- -s si id de ed d   c co ol lo on n L Le ef ft t- -s si id de e   c co ol lo on n A Al ll l   c co ol lo on n R Re ec ct tu um m
O O
1 1) ) S SI IR R 9 95 5% %C CI I O O
1 1) ) S SI IR R 9 95 5% %C CI I O O S SI IR R 9 95 5% %C CI I O O S SI IR R 9 95 5% %C CI I
Parent 70 2 2. .4 45 5 1.91 3.10 44 1 1. .9 90 0 1.38 2.55 128 2 2. .1 11 1 1.76 2.51 42 1 1. .3 39 9 1.00 1.88
Right-sided Sibling 16 6 6. .8 89 9 3.93 11.21 12 5 5. .1 16 6 2.65 9.03 29 5 5. .2 29 9 3.54 7.60 6 1.68 0.60 3.68
colon
Parent  4 3 34 4. .6 62 2 9.00 89.52 0 6 1 16 6. .0 04 4 5.77 35.14 1 10.66 0.00 61.11
and sibling
Parent 51 1 1. .8 85 5 1.38 2.44 48 2 2. .1 15 5 1.58 2.85 113 1 1. .9 94 4 1.60 2.34 52 1 1. .7 79 9 1.33 2.34
Left-side Sibling 10 4 4. .5 56 6 2.17 8.41 4 1.81 0.47 4.68 15 2 2. .8 89 9 1.61 4.77 9 2 2. .6 66 6 1.20 5.06
colon
Parent  2 1 18 8. .5 54 4 1.75 68.18 0 5 1 14 4. .0 00 0 4.42 32.94 0
and sibling
Parent 147 2 2. .1 16 6 1.82 2.53 109 1 1. .9 97 7 1.62 2.38 292 2 2. .0 02 2 1.80 2.27 122 1 1. .4 43 3 1.19 1.71
All colon Sibling 29 5 5. .2 23 3 3.50 7.52 16 2 2. .8 89 9 1.65 4.70 50 3 3. .8 81 1 2.83 5.03 19 2 2. .2 24 4 1.34 3.50
Parent  6 2 21 1. .9 94 4 7.90 48.06 12 1 13 3. .3 39 9 6.88 23.46 1 3.65 0.00 20.94
and sibling
Parent 69 1 1. .5 54 4 1.20 1.95 58 1 1. .5 59 9 1.21 2.05 156 1 1. .6 64 4 1.39 1.92 84 1 1. .7 77 7 1.41 2.19
Rectum Sibling 5 1.38 0.43 3.24 9 2 2. .4 43 3 1.10 4.64 18 2 2. .0 09 9 1.23 3.31 11 1.96 0.97 3.51
Parent  1 5.93 0.00 34.02 0 1 1.69 0.00 9.66 0
and sibling
Bold type, 95% CI does not include 1.00. 
1)Some observed numbers do not add up because in addition to the right- and left-sided colon cancer, multiple and unspecified colon tumours were included.H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(1) 12
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cancer in offspring of affected parents increased to 2.58
(N=138,  95%  CIs  2.17-3.05)  compared  to  the
unchanged sibling risk of 3.81. For right-sided colon
cancer the risk in offspring of affected parents was 3.66
(35, 2.55-5.09); the sibling risk was somewhat increased
from Table 4 because of another definition of the
population to 7.53 (18, 4.46-11.93). For the whole
colon cancer the familial excess risk (SIR minus 1.00)
was 1.8 times higher for siblings (3.81-1.00=2.81) than
for parents of affected parents (2.58-1.00=1.58). 
The  median  diagnostic  age  showed  small
differences between the anatomic sites when parents
were probands (data not shown). However, when
parents were not affected, the median diagnostic
age for sibling with concordant colon and rectal
cancer was 54.3 and 55.9 years, respectively. For
the 16 siblings with concordant right-sided colon
cancer, the median age was 53.3 years, compared
to 56.8 years in those 4 siblings with concordant
left-sided colon cancer. 
The notable difference in sibling risks for right-sided
colon cancer compared to other concordant sites is
illustrated in Fig. 2. By contrast, the SIRs for offspring
of affected parents show only a minor difference. 
In order to search evidence for HNPCC in families of
affected siblings, at least one of whom was diagnosed
with right-sided colon cancer, we listed all first and
second cancer in all their family members. In these 19
families a total of 53 offspring were found, in addition
to those 38 with colon cancer. In one family of two
siblings with right-sided colon cancer a third sibling
was diagnosed with rectal cancer and the father was
diagnosed with pancreatic cancer. This was the only
family with a likely HNPCC diagnosis. However, the
presentation of HNPCC-related tumours was much
more frequent in the 9 families where a parent and at
least two siblings were diagnosed with CRC. 
Effects of diagnostic age for offspring and parents
are shown as contour plots in Fig. 3 for colon cancer
and in Fig. 4 for rectal cancer. The SIR curves have
a linear diagonal direction for colon cancer, indicating
that the diagnostic age of both the offspring and the
parents are inversely related to the risk. SIRs are >10
when both were diagnosed before the age of 50 years.
For rectal cancer, the contour plots are nonlinear; the
highest risk is among young offspring whose parents
were diagnosed at ages around 50 years. Colon was
further divided to right- and left-sided segments (data
not shown). The plot for the right-sided colon resembled
that for the whole colon but with steeper effect of age
at ages below 50 years. The contour for the left-sided
colon cancer resembled that for rectal cancer but the
parental age maximum was 5 years lower. 
I In nt te er rp pr re et ta at ti io on n  o of f  r re es su ul lt ts s  f fo or r  c co ol lo on n  a an nd d  r re ec ct ta al l  c ca an nc ce er r  
There has been a wealth of previous literature on
familial risks in CRC. The review of Johns and Houlston
covered literature until 1999 and it included 27 studies
[11]. The relevant pooled estimates, given as relative
risks of CRC, were 2.42 (95% CIs 2.20-2.65) for colon
cancer in a first degree relative and 1.89 (1.62-2.21)
for rectal cancer in a relative; the CRC risks were 2.26
(1.87-2.72) and 2.57 (2.19-3.02) for a parental and
sibling proband with CRC, respectively. The authors
discussed many aspects of validity of the referred data,
including the need to verify cancer diagnoses of both
the cases and their relatives, which has been achieved
in a limited number of studies. The published results
from the Swedish Family-Cancer Database, with fully
medically verified diagnostic data, have not been
essentially different [38]. However, when colon and
rectal cancers were analysed separately, the SIRs for
colon and rectal cancer by parental proband did not
differ from each other and they were somewhat lower
than the cited figures; on the other hand, the sibling
risks were higher, particularly when colon cancer was
involved [39]. The special features of the present study,
in addition to the size, are focused on adenocarcinoma
only, data on age of onset, separation of colonic
subsites  and  distinction  of  probands.  The  latter
condition allows modes of inheritance to be estimated. 
The known cancer syndromes manifesting CRC
are dominant Mendelian, except for the recently
identified MYH genes exerting recessive effects on
CRC [25]. Biallelic mutations in the MYH gene have
8
7
6
5
4
3
2
1
0
C Ca an nc ce er r   s si it te e
Right-sided
colon
Left-sided 
colon
Proband
Parent Sibling
Colon Rectum
S
S
I
I
R
R
F Fi ig g. .   2 2. .   C Co om mp pa ar ri is so on n   o of f   S SI IR Rs s   o of f   p pa ar re en nt t   a an nd d   s si ib bl li in ng g   p pr ro ob ba an nd d   i in n   C CR RC C
s su ub bs si it te es sH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(1) 13
The Swedish Family-Cancer Database: Update, Application to Colorectal Cancer and Clinical Relevance
S SI IR R
P
P
a
a
r
r
e
e
n
n
t
t
s
s
 
 
a
a
g
g
e
e
 
 
a
a
t
t
 
 
d
d
i
i
a
a
g
g
n
n
o
o
s
s
i
i
s
s
O Of ff fs sp pr ri in ng g   a ag ge e   a at t   d di ia ag gn no os si is s
≥61
51-60
41-50
≤40
≤40                              41-50 51-60 ≥61
F Fi ig g. .   3 3. .   S SI IR R   t tr re en nd d   o of f   c co ol lo on n   c ca an nc ce er r   f fo or r   o of ff fs sp pr ri in ng g   b by y   t th he e   a ag ge es s   a at t   d di ia ag gn no os si is s   o of f   p pa ar re en nt ts s   a an nd d   o of ff fs sp pr ri in ng g   
been found in about 0.5% of CRC patients but only
6 patients have been described in the literature so far
[26, 28]. All except one of these patients presented with
left-sided colon and rectal tumours.  The important new
finding is that risks for siblings were higher than those
for offspring of affected parents but the excess risk
was limited to colon cancer and particularly to
right-sided colon cancer. The SIRs for colon cancer
in age matched populations were 2.58 when parents
were  probands  and  3.81  when  siblings  were
probands; for right-sided colon cancer the SIRs were
3.66 and 7.53, respectively. Thus the familial excess
(SIR-1.00)  was  more  than  two  fold  higher  for
right-sided colon cancer from sibling than parental
probands (6.53 vs. 2.66). As our recent data find no
evidence for an environmental contribution to sibling
risk even for right-sided colon cancer [35], the results
show the existence of a recessive inheritance at this
colonic subsite. In order to exclude known causes of
CRC, we examined the available data on first and
second primary cancer among the affected siblings
and their family members. HNPCC was likely only in
one family, in which 2 siblings were diagnosed with
right-sided colon cancer, because another sibling was
diagnosed with rectal cancer and the father with
pancreatic cancer. If indeed a recessive inheritance
has been found, it does not appear to cause a high
risk of other tumours. Among the 8 sibling pairs with
right-sided colon cancer, none of their other 20
siblings had cancer; only one affected individual was
diagnosed with second cancer, which was in the
cervix.  Similarly,  among  11  sibling  pairs  with
right-sided and left-sided colon cancer, only one of
32 siblings was diagnosed with cancer, which was in
the lung; one of the affected siblings was diagnosed
with a second prostate cancer. Even considering the
diagnosed tumours in parents of these 19 families of the
affected siblings (8 with two right-sided colon cancer
and 11 with pairs of right- and left-sided colon cancers),
no evidence was found for a recognizable cancer
syndrome, except the above family with a likely HNPCC.
It should be pointed out that although previous studies,H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(1) 14
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including the meta-analysis by Johns and Houlston [11],
have not found a difference in the sibling risk for CRC,
the largest family study published outside Sweden did
find a difference [40], and this Danish study was based
on fully medically verified cases, like our present study,
adding credibility to the finding. 
We have reasons to believe that the detected
evidence  on  a recessive  inheritable  cannot  be
explained by MYH mutations. Firstly, in the published
studies only one of 6 patients was diagnosed with
a right-sided colon tumour [26, 28]. Secondly, the
reported frequency, of about 0.5%, appears to be
less than the one noted in the present study. For the
whole colon cancer the familial excess risk was 1.8
times higher for siblings than for parents of affected
parents, suggesting that in this population of 0- to
68-year-old individuals close to half of the familial
risk for colon cancer can be explained by recessive
inheritance. 
Cancers  of  the  colon  and  rectum  are  often
considered together as CRC because of biological and
functional similarity [41, 42]. However, there is evidence
that the colon and the rectum respond differently to the
main risk factors, such as obesity and physical activity
[43]. The previous data on the possible role of the family
history have been inconclusive because of small numbers
but,  for  example,  HNPCC  is  known  to  have
a predilection for proximal, right-sided colon cancer
[17, 39, 41]. The present data show that the familial SIR
for offspring of affected parents is not different between
colon (SIR 2.02) and rectal (1.77) cancer. On the other
hand, sibling risk is appreciably higher for the colon
(3.81) than for the rectum (1.96, borderline significance).
Moreover, familial triplets of two or more affected siblings
in families of affected parents were only found for colon
cancer (SIR 13.39). Thus colon and rectum appear to
be distinguished between high-penetrant and recessive
conditions  that  only  affect  the  colon,  whereas
low-penetrant familial effects are shared by the two sites. H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(1) 15
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Effects of diagnostic age for offspring and parents
showed different types of contour plots for colon and
rectal  cancer.  The  SIR  curves  followed  a linear
diagonal pattern for colon cancer, indicating that the
diagnostic age of both the offspring and the parents
were inversely related to the risk. SIRs are >10 when
both were diagnosed before the age of 50 years. 
For rectal cancer, the contour plots were nonlinear,
the highest risk being found for young offspring whose
parents were diagnosed at ages around 50 years.
The plot for the right-sided colon resembled that for
the whole colon but with steeper effect of age at ages
below 50 years. The contour for the left-sided colon
cancer resembled that for rectal cancer but the
parental age maximum was 5 years lower. The other
relevant new data relate to sibling risks. Particularly
in colon cancer, the majority of the affected siblings
presented with a relatively late onset disease and
without  an  affected  parent,  thus  suggesting
involvement of low-penetrance or recessive genes
unrelated to HNPCC. These non-HNPCC familial
CRCs  will  probably  be  difficult  to  characterize
genetically, because they may be heterogeneous with
low penetrance, recessive mode and no strong
association to other types of cancers. 
C Cl li in ni ic ca al l   u us se e   o of f   d da at ta a   o on n   f fa am mi il li ia al l   r ri is sk ks s
The algorithms for clinical genetic counselling need
to be based on reliable data on familial risks with
consideration  of  the  genetic  data  on  possible
underlying genes [44]. For cancer syndromes with
identified genes, mutation testing may be offered.
However,  the  known  syndromes  cover  a small
proportion of familial aggregation of cancer and
counselling has to rely on epidemiologically derived
risk estimates. Indeed, many risk estimation models
were developed before any genes were identified, and
for prostate cancer no established genes can yet be
offered for testing. The two clinically-utilised models
for breast cancer risk assessment were devised before
the identification of the highly penetrant breast cancer
susceptibility genes. The Gail model predicts a woman’s
risk for breast cancer, based on her individual risk
factors, including a family history [45]. The model was
developed using data from a large follow-up study.
The Gail model has been evaluated in several settings
and it has been found to give reasonably accurate
predictions of risk [46]. The Claus model has been
developed based on a case-control study and it has
been useful for the estimation of heritable risks of breast
cancer [47]. However, because neither of these models
takes into account family history, hormonal factors and
benign breast disease comprehensively, both models
have been found to systematically underestimate risk
of developing cancer in women who attend a cancer
genetics clinic [48]. A recent model which does take
all these factors into account, the Tyrer-Cuzick model,
appears  to  be  more  consistently  accurate  [49]. 
These are examples of how detailed epidemiological
data provide relatively valid risk predictions in the
absence of mutation analysis. Once mutational data
become  known,  a further  refinement  of  the  risk
assessment models must necessarily be done. 
In low-penetrant cancers, familial aggregation is
present,  but  Mendelian  patterns  cannot  be
ascertained, genetic mechanisms have not been
worked out and the only types of available risk
estimates are derived from epidemiological studies.
In many cancers, different levels of familial risk can
be  discerned  without  aetiological  explanation. 
For example, the Groningen Database on familial cancer,
the Familial Cancer Database (http://www.facd.info)
contains a large number of data on familial cancer
clusters  in  which  no  specific  genes  have  been
identified, yet with a great importance to clinicians
and other specialists who have to advise patients and
their families [50]. Typically, prostate cancer displays
high-risk and lower-risk familial clusterings, depending
on the age of onset and family relationships. Clinical
genetic  counselling  is  currently  based  on  these
parameters. For some cancers, screening tests are
available and they may be recommendable in familial
cases, irrespective of whether the genetic background
of the disease is known. However, for most familial
cancers  risk  estimates  are  only  derived  from
epidemiological studies of the kind proposed in the
present application. Familial cancer clustering, without
obvious heritability, poses a major challenge to
current cancer risk assessment and management.
Reliable determination of familial risks for cancer is
important  for  clinical  genetic  counselling,  but
medically verified data on familial risks for many
malignancies have been limited. The data on familial
risk generated in population-based studies are helpful
in  implementing  evidence-based  guidelines  for
helping the general medical system to ascertain and
refer even familial cancer clusters to cancer genetic
professionals. Familial SIR and relative risks need to
be translated to the individual-based risk estimates
useful in cancer genetics counselling. 
Expert bodies, such as the American Cancer Society
have considered a family history as an indication for
screening or surveillance only for cancers of the breast,.
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prostate, colorectum, endometrium for reasons of cost-
effectiveness and the perceived impact on public health
at large [51]. Such guidelines may miss many other
familial cancers of moderate risk. Familial cancer risks
ascertained by population-based databases suggest that
the bulk of cancers may be included in this moderate
risk category, which does demand increased clinical
surveillance and screening [6]. We have estimated that
the American Cancer Society Guidelines on familial
colorectal cancer surveillance consider a familial risk of
2.2 an action level and recommend regular clinical
screening [6]. Of course, many types of data need to
be considered for an action level for familial cancer
clusterings, but a familial risk of 2.2 will be exceeded in
many cancers, at least in some subgroups. 
The level of cancer genetics services varies extensively
nationally and internationally. In advanced clinics the
counsellor pays attention to the number of affected
family members with any kind of cancer as well as the
age of onset [52]. The other extreme is that no attention
is paid to the family history, although in the past years
the level of knowledge on genetic causes for breast,
colorectal and some other cancers has reached all
modern cancer clinics. However, even if cancer genetics
services are in place, there are two other important
factors that must be considered [44]. First, the primary
health service at the front end of the referral chain,
needs to take a family history, to recognise familial
cancer clusterings and to communicate the significance
of this to the patient [53]. Second, the patients need to
understand the significance of an increased familial
cancer risk such that an appointment with a cancer
genetics professional is made and kept. 
The successes in early diagnosis and management
of heritable cancers have shown evidence that inherited
cancers are no longer inevitable. Although genetic
testing has become an important method for at-risk
families of certain cancers, it covers a small proportion
of all familial cancers. Empirical risk estimates from
epidemiological studies have proven to be useful for
familial  breast  and  prostate  cancers,  and  it  is
recommended that reliable risk estimates for other
cancers also be seriously considered for routine clinical
recommendations. A familial low-penetrant risk in
a common cancer may result in more cases in a given
population  than  a high  risk  of  a rare  cancer.
Furthermore, familial risks are higher for some relatively
rare  neoplasms,  causing  hardship  in  the  affected
families. Implementation of a unified management plan
for familial cancers at large will be a challenge to the
involved professionals, the patients and their families
and the societies. 
C Co on nc cl lu us si io on ns s
Clinical presentation of a cancer, combined with
a family history, may be pathognomonic, diagnostic or
suggestive  of  a syndrome  and  a cancer  genetics
professional may readily be able to recommend a gene
test in the setting of genetic counselling. However, when
syndrome-defining features are lacking, as in the case
of mutation-negative familial breast and colorectal
cancer clusters, or in low-penetrant cancers, familial
aggregation is present, but Mendelian patterns cannot
be ascertained, genetic mechanisms have not been
worked out and the only types of available risk estimates
are derived from epidemiological studies. For some
cancers, screening tests are available and they may be
recommendable in familial cases, irrespective of whether
the genetic background of the disease is known. Familial
cancer clustering, without obvious heritability, poses
a major challenge to current cancer risk assessment and
management. It will be an important task to translate
the population-based data on familial risks to the
individual-based cancer genetics counselling. 
Sometimes familial cancers are dismissed because
they are relatively rare among cancers at any sites. The
rareness is true, but, in addition to age, family history
is probably the only known risk affecting all types of
cancer. For some cancers, such as prostate cancer, it
is the most prevalent risk factor, after age. There is
a further argument for the study of familial cancers.
Many of the genes that underlie heritable cancer
syndromes are also important in sporadic cancers as
somatic events. The gene for Li-Fraumeni syndrome,
p53, is the most common somatic genetic alteration
in cancer, found in half of all cancers. Other examples
are the APC and VHL genes in colorectal and renal
cancers, respectively. However, even if this paradigm
has not been true for BRCA1/2, one of the major
motivations for studying familial/heritable cancers is
the belief that they will contribute to the understanding
of cancers at large. Through uncommon cancers we
probably learn more about common cancers. 
Finally, epidemiological results on familial risk,
familial SIRs, are sometimes dismissed because ”they
cannot be translated into individual risks”. In this article
we  show  several  examples  on  every-day  use  of
epidemiological data in clinical risk estimation. In fact,
in the absence of known genes, reliable individual risk
estimates need to be generated among populations. 
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